The advantages of improved laboratory diagnosis are evident, because 30 % of the RA patient population cannot be identified applying diagnostic testing for ACPA and/or rheumatoid factor (RF) [8]. The gene discussed is PRTN3; the disease is rheumatoid arthritis.